The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Multitude Therapeutics’ AMT-253 Breakthrough Therapy Designation
December 17, 2025, according to the official websi…
Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Multitude Therapeutics, Inc., a clinical stage bio…
Multitude Therapeutics Announces Promising Interim Phase I/II Results from the Ongoing First-in-Human Study Evaluating its CD44v9-directed Antibody-Drug-Conjugate, AMT-116, in Heavily Pretreated EGFR Wild-type Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting
Multitude Therapeutics, Inc., a clinical-stage com…